Skip to main content Accessibility help
×
Home
Hostname: page-component-56f9d74cfd-w6k7h Total loading time: 0.715 Render date: 2022-06-26T00:15:08.370Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

9 - Perphenazine and Perphenazine Decanoate

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

As with many first-generation antipsychotics (FGAs), perphenazine has no unique therapeutic benefit compared to other D2 antagonists, but does have a long-acting injectable (LAI) preparation available in certain parts of the world (Belgium, Denmark, Finland, Iceland, The Netherlands, Norway, Portugal, Sweden) and a large database of plasma level information. As the FGA arm of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, many clinicians came to appreciate that modest perphenazine dosages are effective, that perphenazine is associated with lower metabolic risk than many second-generation antipsychotics, and that perphenazine treatment is associated with less prolactin elevation than risperidone therapy [2, 3].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 190 - 200
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Linnet, K. and Wiborg, O. (1996). Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther, 60, 4147.
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 12091223.
Meyer, J. M., Davis, V. G., Goff, D. C., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res, 101, 273286.
Sweet, R. A., Pollock, B. G., Mulsant, B. H., et al. (2000). Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol, 20, 181187.
Jin, Y., Pollock, B. G., Coley, K., et al. (2010). Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol, 50, 7380.
Hansen, L. B. and Larsen, N. E. (1985). Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berl), 87, 1619.
Mazure, C. M., Nelson, J. C., Jatlow, P. I., et al. (1990). The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry, 51, 330334.
Kistrup, K., Gerlach, J., Aaes-Jorgensen, T., et al. (1991). Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients: serum levels at the minimum effective dose. Psychopharmacology, 105, 4248.
Talvik, M., Nordstrom, A. L., Larsen, N. E., et al. (2004). A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology, 175, 148153.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.
Mylan Pharmaceuticals Inc. (2018). Perphenazine package insert. Morgantown, WV.
Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629651.
Olesen, O. V. and Linnet, K. (2000). Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol, 50, 563571.
Dahl-Puustinen, M. L., Liden, A., Alm, C., et al. (1989). Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther, 46, 7881.
Ozdemir, V., Naranjo, C. A., Herrmann, N., et al. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther, 62, 334347.
Mulsant, B. H., Foglia, J. P., Sweet, R. A., et al. (1997). The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol, 17, 318321.
Halayqa, M. and Domanska, U. (2014). PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release. Int J Mol Sci, 15, 2390923923.
Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl, 52, S1319.
Knudsen, P., Hansen, L. B., Auken, G., et al. (1985). Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl, 322, 1528.
Tuninger, E. and Levander, S. (1997). Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatr Scand, 96, 347353.
Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 1428.
Orion Pharma AB (2017). Trilafon Dekanoat. Danderyd, Sweden.
Larsen, N. E. and Hansen, L. B. (1989). Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks. Ther Drug Monit, 11, 642646.
Dencker, S. J., Giös, I., Mårtensson, E., et al. (1994). A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berl), 114, 2430.
Marder, S. R., Midha, K. K., Van Putten, T., et al. (1991). Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry, 158, 658665.
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.
Eggert Hansen, C., Rosted Christensen, T., Elley, J., et al. (1976). Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol, 3, 915923.
Hansen, L. B. and Larsen, N. E. (1977). Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology, 53, 127130.
Hansen, L. B., Larsen, N. E., and Gulmann, N. (1982). Dose–response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl), 78, 112115.
Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500505.
Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254264.
Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255261.
Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269274.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×